Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598181 | 0.91 | TRPV1 (0.47) | TRPV1CASP3CA9CRBN | |
| SCHEMBL3600259 | 0.86 | CA9 (0.33) | TRPV1LCKCA9CRBN | |
| SCHEMBL3603349 | 0.86 | TRPV1 (0.42) | TRPV1CASP3PDE3BPDE3A | |
| SCHEMBL3605984 | 0.85 | TRPV1 (0.39) | TRPV1CA9CRBN | |
| SCHEMBL3601169 | 0.81 | CA9 (0.37) | CA9CRBN | |
| SCHEMBL3597873 | 0.80 | CA9 (0.40) | TRPV1CASP3CA9CRBN | |
| SCHEMBL3600214 | 0.79 | TRPV1 (0.47) | TRPV1CASP3 | |
| SCHEMBL3598578 | 0.77 | RET (0.35) | CA9CRBN | |
| SCHEMBL13383402 | 0.77 | TRPV1 (0.54) | TRPV1CASP3 | |
| SCHEMBL3588367 | 0.77 | CA9 (0.41) | TRPV1CA9CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | TRPV1 2518/4885CASP3 106/4885PDE3B 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.